Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:27 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 5,901 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Placebo product Clear all

Conditions: Healthy Subjects
Interventions: 0.5 mg/kg Lpathomab, 1.0 mg/kg Lpathomab, 3.0 mg/kg Lpathomab, 10 mg/kg Lpathomab, 20 mg/kg Lpathomab, Saline solution for intravenous infusion; Biological · Other
Lead sponsor: Lpath, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Surgical Wounds, Mohs Surgery
Interventions: Topical Timolol, Normal Saline; Drug
Lead sponsor: Geisinger Clinic; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Danville, Pennsylvania

Conditions: Abdominal Abscess
Interventions: Gentamicin Sulfate Inj 20mg/2ml vial for injection, Clindamycin phosphate 6 mg/1ml for injection, Placebo; Drug · Other
Lead sponsor: University of Iowa; Other
Eligibility: 18 Years to 80 Years
Enrollment: 2 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Parkinson's Disease
Interventions: Placebo, IPX066 95 mg LD, IPX066 145 mg LD, IPX066 195 mg LD, IPX066 245 mg LD; Drug
Lead sponsor: Impax Laboratories, LLC; Industry
Eligibility: 30 Years and older
Enrollment: 381 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 27
States / cities: Birmingham, Alabama • Phoenix, Arizona • Garden Grove, California + 22 more

Conditions: Sleep Initiation and Maintenance Disorders, Depression
Interventions: Estrogen Replacement Therapy, Zolpidem, placebo; Drug
Lead sponsor: Hadine Joffe, MD; Other
Eligibility: 40 Years to 60 Years · Female only
Enrollment: 86 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Photodamaged Skin
Interventions: Imedeen, Placebo; Dietary Supplement
Lead sponsor: Pfizer; Industry
Eligibility: 35 Years to 65 Years · Female only
Enrollment: 194 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 4
States / cities: Miami, Florida • Fair Lawn, New Jersey • Lynchburg, Virginia + 1 more

Conditions: HIV Infections
Interventions: Nevirapine, Zidovudine; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 13 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 5
States / cities: Oakland, California • Chicago, Illinois • Baltimore, Maryland + 2 more

Conditions: Healthy Volunteers
Interventions: Danicamtiv, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Anaheim, California

Conditions: Neuropathic Pain, Postmastectomy Pain
Interventions: Lidoderm patch, Placebo patch; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older · Female only
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2007
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Healthy
Interventions: Placebo, Flavonoids, Flavonoids+Prebiotics; Other · Dietary Supplement
Lead sponsor: Pharmanex; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 27 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: Logan, Utah

Conditions: Asthma
Interventions: Albuterol dry powder inhaler, Albuterol HFA MDI (hydrofluoroalkane metered dose inhaler); Drug
Lead sponsor: Teva Branded Pharmaceutical Products R&D, Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 9
States / cities: Los Angeles, California • Denver, Colorado • Lakewood, Colorado + 5 more

Conditions: Naltrexone HCl 50 MG Oral Tablet, Placebo
Interventions: Naltrexone Oral Product, Placebo; Drug
Lead sponsor: Texas Tech University; Other
Eligibility: 18 Years to 120 Years
Enrollment: 7 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Alzheimer Disease, Mild Cognitive Impairment
Interventions: Placebo, Eligard 22.5Mg Suspension for Injection; Drug
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 60 Years to 120 Years · Female only
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 3
States / cities: Boca Raton, Florida • New York, New York • Madison, Wisconsin

Conditions: Decompensated Heart Failure
Interventions: Lysine Chloride, Placebo; Drug · Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Drug Dependence
Interventions: 2-4 of the drugs listed below; Drug
Lead sponsor: University of Arkansas; Other
Eligibility: 18 Years to 65 Years
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Rheumatoid Arthritis
Interventions: Natrunix, Placebo; Drug
Lead sponsor: XBiotech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 243 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 26
States / cities: Covina, California • Encino, California • Rancho Mirage, California + 19 more

Conditions: Healthy
Interventions: cangrelor, moxifloxacin, placebo; Drug
Lead sponsor: The Medicines Company; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008
U.S. locations: 1
States / cities: Tacoma, Washington

Conditions: Amyotrophic Lateral Sclerosis, Frontotemporal Dementia
Interventions: TPN-101, 400 mg/day, Placebo; Drug
Lead sponsor: Transposon Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 10
States / cities: La Jolla, California • Orange, California • San Francisco, California + 5 more

Conditions: Liver Cirrhosis, Sarcopenia
Interventions: LPCN 1148, Placebo; Drug
Lead sponsor: Lipocine Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 10
States / cities: Scottsdale, Arizona • Los Angeles, California • San Francisco, California + 6 more

Conditions: Myocardial Bridging
Interventions: Nebivolol, Diltiazem, Placebo; Drug · Other
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 1
States / cities: Stanford, California

Conditions: Pain
Interventions: Baclofen 10mg, Placebo; Drug · Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Osteoarthritis of the Knee
Interventions: Infliximab, Placebo, Standard of Care: Methylprednisolone acetate; Drug
Lead sponsor: Herbert Lindsley, MD; Other
Eligibility: 35 Years to 85 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Urinary Tract Infections
Interventions: LBP-EC01 0.1 x IV dose, LBP-EC01 0.01x IV Dose, LBP-EC01 IV Infusion Dose, Placebo, LBP-EC01, TMP/SMX; Drug
Lead sponsor: Locus Biosciences; Industry
Eligibility: 18 Years to 75 Years · Female only
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 17
States / cities: Fresno, California • Lancaster, California • Los Angeles, California + 13 more

Conditions: Basal Cell Carcinoma, Basal Cell Nevus Syndrome
Interventions: Dietary Vitamin D3 pre-treatment, Photodynamic therapy, Serum Maintenance Vitamin D3; Drug · Radiation
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: Not listed
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2023
U.S. locations: 2
States / cities: Phoenix, Arizona • Cleveland, Ohio

Search by objective public record fields.

A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers

The Effects of Timolol On Healing and Cosmesis of Mohs Scalp Wounds: An Open Label Trial

Antibiotic Irrigations for Intra-Abdominal Drains

A Study To Evaluate The Safety And Efficacy Of IPX066 In Subjects With Parkinson's Disease

Estrogen for Treating Depression in Menopausal Women With Hot Flashes and Insomnia

A Study to Assess the Effects of an Oral Dietary Supplement on Overall Facial Appearance Among Healthy Adult Women With Existing Skin Damage From Sun Exposure

A Multi-Center, Placebo-Controlled, Double-Blind, Randomized Trial Comparing the Virologic and Immunologic Activities of 400 Mg Nevirapine in Combination With Zidovudine Versus Zidovudine Alone in Asymptomatic HIV-1 Infected Patients With 4-12 Months of Prior Zidovudine Therapy and 200-500 CD4+ Cell

A Study to Evaluate the Safety, Tolerability, and Drug Levels of Danicamtiv in Healthy Japanese and Caucasian Participants

Symptom Management After Breast Cancer Surgery

Effect of a Proprietary Dietary Supplement on Fecal Volatile Organic Compounds

A Cumulative Dose Study to Evaluate the Safety and Efficacy of Albuterol in a Dry Powder Inhaler and an HFA MDI (Hydrofluoroalkane Metered Dose Inhaler)

Naltrexone for Prolonged Grief Disorder

The LUCINDA Trial: LeUprolide Plus Cholinesterase Inhibition to Reduce Neurological Decline in Alzheimer's

Mechanism and Effects of Manipulating Chloride Homeostasis in Stable Heart Failure

Drug Discrimination in Methadone-Maintained Humans Study 3

Natrunix or Placebo in Combination With Methotrexate in Rheumatoid Arthritis

Assess the Effect of Cangrelor at the Therapeutic Dose and a Supratherapeutic Dose Level on the QT/QTc Interval in Healthy Volunteers

A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD

A Study to Assess the Efficacy, Safety, and Tolerability of Oral LPCN 1148 in Male Subjects With Cirrhosis of the Liver and Sarcopenia

Efficacy of Medical Therapy in Women and Men With Angina and Myocardial Bridging

Baclofen as a Perioperative Analgesic Adjuvant

Treatment Of Knee Osteoarthritis With Intra-Articular Infliximab

A Study of LBP-EC01 in the Treatment of Acute Uncomplicated UTI Caused by Drug Resistant E. Coli (ELIMINATE Trial)

Vitamin D as a Nutritional Neoadjuvant During Photodynamic Therapy of Basal Cell Carcinoma